Kidney International June issue nephrology picks

The International Society of Nephrology used its ISNkidneycare X account on May 21 to point readers to Kidney International’s June issue and its online table of contents. The post highlighted editor’s picks and recent nephrology research updates tied to the journal’s June package. Kidney International is the society’s flagship journal, published by Elsevier, and its recent articles show a June issue centered on chronic kidney disease, glomerular disease and emerging immune therapies. ### Which June papers appear to anchor the issue? Kidney International’s recent article pages show several June-dated themes already in circulation. A review on chronic kidney disease said new therapies have shifted the field “from slowing inevitable progression to achievable remission,” citing trial evidence for sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide 1 receptor agonists and targeted immunotherapies for IgA nephropathy. (x.com) A separate Kidney International commentary revisited how kidney studies are designed. That article said the International Society of Nephrology convened a two-day multi-stakeholder meeting to map out a road map for advancing clinical research in nephrology, including broader use of patient-reported outcome measures and innovative trial designs. ### Why is IgA nephropathy getting so much attention? (kidney-international.org) Kidney International published a recent editorial arguing that IgA nephropathy may not be explained by IgA1 alone. The article said Li and colleagues showed IgA2 is consistently deposited in glomeruli in IgA nephropathy and promotes complement activation, macrophage infiltration and mesangial cell activation, challenging what it called an “IgA1-centric paradigm.” (kidney-international.org) Another June-linked article focused on treatment rather than mechanism. A Kidney International review on complement inhibitors and B cell–modifying agents for IgA nephropathy said drug development has accelerated since KDIGO updated its glomerular disease guideline in 2021, with several novel therapies now tested and approved. ### What stood out in pediatric nephrology? A Kidney International editorial on childhood idiopathic nephrotic syndrome pointed to a push toward more individualized treatment. (kidney-international.org) The article said Tu and colleagues developed a polygenic risk score that combines clinical data with human leukocyte antigen class II variants to stratify steroid responsiveness at diagnosis, while adding that predictive performance remains modest and is not ready for immediate clinical use. (kidney-international.org) That piece framed the study as part of a broader precision-medicine effort in pediatric nephrology. The authors said a presentation-only model is unlikely to predict the full later disease course, but described the work as a conceptual framework for future risk stratification. ### What does the issue say about inflammation and vascular injury? Kidney International also published work on hypertension-associated kidney injury in Dahl salt-sensitive rats. (kidney-international.org) That article said Feng and colleagues identified C-C motif chemokine ligand 2, or CCL2, as a direct regulator of kidney microvascular smooth muscle contractility, linking inflammatory signaling to impaired autoregulation and vascular damage. A separate review on chronic kidney disease microvasculature examined angiopoietin-2 inhibition and TIE2 reactivation. The article described endothelial loss and capillary rarefaction as defining features of chronic kidney disease and argued those pathways may offer therapeutic targets. ### Which therapies are being watched beyond standard immunosuppression? Kidney International recently published an article on T-cell engagers and deep immune-cell depletion. (kidney-international.org) That review said chimeric antigen receptor T cells and T-cell engagers, first developed for hematologic cancers, are now showing efficacy in autoimmune disease and documented the first successful use of a B-cell maturation antigen-targeting T-cell engager to induce human plasma-cell depletion. (kidney-international.org) KDIGO-related material in the journal also points to a broader treatment agenda in 2026. The executive summary of the KDIGO 2026 anemia in chronic kidney disease guideline was published in Kidney International volume 109, issue 1, according to the guideline PDF and journal page. ### Where can readers follow the June package from here? The International Society of Nephrology’s May 21 post directed readers to Kidney International’s June table of contents online. (kidney-international.org) Kidney International’s website hosts issue navigation, article pages and full-text access for many editorials, reviews and guideline papers tied to volume 109. The next step for readers is the journal’s June issue page itself, where editor’s picks and linked articles are being surfaced as the issue rolls out online. (kidney-international.org) (x.com)